Virginia Gov. Abigail Spanberger has vetoed closely watched legislation that would have established an advisory panel aimed at reducing the cost of prescription drugs, a move that disappointed lawmakers across the United States who had been pushing for such measures. Unlike similar boards in other states, Virginia's proposed panel was designed to use Medicare as its benchmark. Each year, the panel would focus on the same drugs selected by Medicare for price negotiations, aiming to set upper payment limits and create a ceiling on what would be paid out.
This approach differed significantly from plans in other states that are at various stages of establishing affordability boards. Of the nine other states with such panels, none is targeting all the same drugs chosen annually by Medicare, and only four have the authority to set upper payment limits.
The veto comes as many U.S. lawmakers continue to grapple with the rising costs of prescription medications, prompting efforts in multiple jurisdictions to address this issue through various mechanisms. Virginia's proposed panel was seen as a potential model for other states looking to implement similar measures, but its defeat highlights the challenges involved in crafting legislation that can effectively influence drug pricing without being overly prescriptive.
By vetoing the bill, Gov. Spanberger has sent a signal that more work is needed before such an advisory panel could be established in Virginia. The full story at STAT+ continues to explore these issues and potential solutions for lowering prescription drug costs nationwide. Continue to STAT+ to read the full story…
